The growing R&D activities to develop drugs for previously untapped markets (elderly population of ages more than 60) is one of the biggest upcoming trend for the human respiratory syncytial virus (RSV) drugs market. For instance, Novovax's RSV-F Vaccine for RSV prophylaxis for people more than 60 years of age is already in the advanced stage of development and is expected to be launched over the forecast period.

PART 01: Executive summary 6

Highlights 7
PART 02: Scope of the report 8

 Market overview 8

Top-vendor offerings 10
PART 03: Market research methodology 11

Research methodology 11

Economic indicators 11
PART 04: Introduction 12

Key market highlights 12
PART 05: Disease overview 14

Understanding the disease 14

Symptoms 14

Causes 15

Risk factors 15

Complications 16

Tests and diagnosis 16

Key buying criteria 17
PART 06: Pipeline analysis 20

PART 07: Market landscape 23

Global respiratory syncytial virus drugs market 23

Five forces analysis 29
PART 08: Market segmentation by category of drug 30

Approved Drugs 30

Off-label drugs 30
PART 09: Geographical segmentation 31

Human respiratory syncytial virus drugs market in US 32

Human respiratory syncytial virus drugs market in Europe 34

Human respiratory syncytial virus drugs market in ROW 35
PART 10: Market drivers 38

Presence of large patient pool fuels market growth 38

Launch of novel products 39

 Novel diagnostic tools increase patient population 40
PART 11: Impact of drivers 41

PART 12: Market challenges 42

Continuous change in guidelines from healthcare organizations impacts market growth 42

Cyclical nature of market hinders growth opportunities 43

Limited drugs in market leading to low penetration rates 44
PART 13: Impact of drivers and challenges 46

PART 14: Market trends 47

Emergence of new entrants likely to change market dynamics 47

Growing strategic collaborations fostering innovation 48

Active participation from emerging economies toward R&D 49
PART 15: Vendor landscape 50

 Competitive scenario 50
PART 16: Key vendor analysis 56

AstraZeneca 56

AbbVie 60

GSK 62

Teva Pharmaceutical 66

Other prominent vendors 69
PART 17: Appendix 72

List of abbreviations 72
PART 18: Explore Technavio 73